Calithera Biosciences Inc. (NASDAQ:CALA)’s share price reached a new 52-week low on Monday . The stock traded as low as $3.55 and last traded at $3.55, with a volume of 209,140 shares changing hands. The stock had previously closed at $3.63.

A number of equities analysts have commented on the stock. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Calithera Biosciences in a research report on Thursday, May 12th. Zacks Investment Research cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, May 17th. Finally, JMP Securities reaffirmed a “buy” rating on shares of Calithera Biosciences in a research report on Wednesday, June 8th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Calithera Biosciences has a consensus rating of “Buy” and a consensus target price of $10.48.

The stock’s 50 day moving average price is $4.56 and its 200 day moving average price is $5.41. The firm’s market capitalization is $65.96 million.

Calithera Biosciences (NASDAQ:CALA) last issued its earnings results on Tuesday, May 10th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by $0.05. Equities analysts forecast that Calithera Biosciences Inc. will post ($2.15) EPS for the current year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.